Search Results
68 items found for "Omass Therapeutics"
- Ep 34 with Dr. Brian Arey
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy
Despite their crucial role in regulating antitumor immunity and tumorigenesis, therapeutic applications
- Ep 59 with Dr. Nicola J. Smith
orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic
- Ep 16 with Dr. Aaron Sato
record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics
- Ep 80 with Dr. Andrew Tobin
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Ep 31 with Dr. Kevin Pfleger
Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics
- Dopamine-Mediated Motor Recovery after Ischemic Stroke
We hope our research will aid in the development of new therapeutic interventions for the alleviation
- Illuminating Functional Selectivity and Allosterism at GPCRs.
He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director
- Ep 70 with Dr. Stephen Ferguson
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Applying Pharmacology to Drug Discovery
What makes each drug type unique to therapeutic pharmacology? 3.
- Ep 69 with Dr. Stephen Ferguson
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Ep 53 with Dr. Timo De Groof
nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic
- GPCR Retreat 2023 - Part I
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Enterococcus-derived tyramine hijacks α2A-adrenergic receptor in intestinal stem cells to exacerbate colitis
a causal link between microbial regulation of ISCs and colitis exacerbation and yielding a targeted therapeutic
- Distinct sub-cellular signal propagation as a component of functional selectivity
of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics
- GPR56 signaling pathway network and its dynamics in the mesenchymal transition of glioblastoma
heterogeneously in glioblastoma (GBM) and is involved in the mesenchymal transition, making it a promising therapeutic
- AGPCR 24 Session VI
lab succeeded in translating their findings from basic research into the preclinical evaluation of therapeutic particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically She is working on developing novel therapeutics for glioma, in particular targeting adhesion-GPCR CD97
- Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration
interplay between CXCR4 and HRH1, and suggest the possibility of the CXCR4-HRH1 heteromer as a potential therapeutic
- Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer
Furthermore, their modulation could be considered as a promising approach in lung cancer therapeutics
- Ep 113 with Dr. Prasenjit Saha
receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
Moreover, the S1P signaling genes are promising therapeutic targets and plausible new innovation avenues
- Ep 153 with Dr Jacek Mokrosiński
Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations
- Ep 146 with Dr Michael Feigin
Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic
- Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma
mediator in the advancement of OSCC, offering a potential avenue for the development of innovative therapeutic
- CaaX-motif-adjacent residues influence G protein gamma (Gγ) prenylation under suboptimal conditions
Pharmacological inhibition of the lipid synthesis pathway by statins is a therapeutic approach to control
- Advanced data analysis for GPCR pharmacology
drug action and is known for applying binding and signaling kinetics to the development of effective therapeutics
- Wnt pathway inhibition with the porcupine inhibitor LGK974 decreases trabecular bone but not fibrosis in a murine model with fibrotic bone
targeting the Gs-GPCR or components of the downstream signaling pathway could serve as a promising therapeutic
- GPR15 expressed in T lymphocytes from RA patients is involved in leukocyte chemotaxis to the synovium
Our results suggest that GPR15/GPR15L have a pathogenic role in RA and their antagonizing could be a therapeutic